Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results

[1] Mansour EG(1989)Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study N Engl J Med 320 485-490

[2] Gray R(1997)Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer J Natl Cancer Inst 89 1673-1682

[3] Shatila AH(2001)Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes J Natl Cancer Inst 93 112-120

[4] Osborne CK(2017)Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual CA Cancer J Clin 67 290-303

[5] Tormey DC(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826

[6] Gilchrist KW(2008)Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol 26 721-728

[7] Cooper MR(2015)Prospective validation of a 21-gene expression Assay in breast cancer N Engl J Med 373 2005-2014

[8] Falkson G(2010)The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features Cancer Investig 28 969-977

[9] Fisher B(2012)Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 131 413-424

[10] Dignam J(2013)Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis Breast 22 879-886

[1] Mansour EG(1989)Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study N Engl J Med 320 485-490

[2] Gray R(1997)Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer J Natl Cancer Inst 89 1673-1682

[3] Shatila AH(2001)Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes J Natl Cancer Inst 93 112-120

[4] Osborne CK(2017)Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual CA Cancer J Clin 67 290-303

[5] Tormey DC(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826

[6] Gilchrist KW(2008)Development of the 21-gene assay and its application in clinical practice and clinical trials J Clin Oncol 26 721-728

[7] Cooper MR(2015)Prospective validation of a 21-gene expression Assay in breast cancer N Engl J Med 373 2005-2014

[8] Falkson G(2010)The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features Cancer Investig 28 969-977

[9] Fisher B(2012)Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 131 413-424

[10] Dignam J(2013)Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis Breast 22 879-886